Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia-Reference-Cited by-同舟云学术

Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Published:2008-07 Issue:1 Volume:54 Page:170-180
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Debruyne Frans,Gres Arkadij A.,Arustamov Dmitrii L.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old;Rhodes;J Urol,1999

2. Natural history of benign prostatic hyperplasia;Jacobsen;Urology,2001

3. BPH treatment: a paradigm shift;Tubaro;Eur Urol,2006

4. The long-term outcome of medical therapy for BPH;Madersbacher;Eur Urol,2007

5. Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia;Comaru-Schally;J Clin Endocrinol Metab,1998

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update;Expert Opinion on Emerging Drugs;2024-06-14

2. The Future of Management of Benign Prostatic Hyperplasia;The Big Prostate;2017-08-25

3. Emerging drugs for the treatment of benign prostatic hyperplasia;Expert Opinion on Emerging Drugs;2017-07-03

4. The GnRH Antagonist Degarelix Directly Inhibits Benign Prostate Hyperplasia Cell Growth;Hormone and Metabolic Research;2015-07-21

5. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia;Expert Opinion on Investigational Drugs;2015-05-18